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Abstract
Background: The implication of nitric oxide (NO) in the development of human African trypanosomiasis (HAT) using an
animal model, was examined. The manner by which the trypanocidal activity of NO is impaired in the periphery and in the
brain of rats infected with Trypanosoma brucei brucei (T. b. brucei) was analyzed through: (i) the changes occurring in NO
concentration in both peripheral (blood) and cerebral compartments; (ii) the activity of nNOS and iNOS enzymes; (iii)
identification of the brain cell types in which the NO-pathways are particularly active during the time-course of the
infection.
Methodology/Principal Findings: NO concentration (direct measures by voltammetry) was determined in central (brain)
and peripheral (blood) compartments in healthy and infected animals at various days post-infection: D5, D10, D16 and D22.
Opposite changes were observed in the two compartments. NO production increased in the brain (hypothalamus) from D10
(+32%) to D16 (+71%), but decreased in the blood from D10 (222%) to D16 (246%) and D22 (260%). In parallel with NO
measures, cerebral iNOS activity increased and peaked significantly at D16 (up to +700%). However, nNOS activity did not
vary. Immunohistochemical staining confirmed iNOS activation in several brain regions, particularly in the hypothalamus. In
peritoneal macrophages, iNOS activity decreased from D10 (283%) to D16 (265%) and D22 (274%) similarly to circulating
NO.
Conclusion/Significance: The NO changes observed in our rat model were dependent on iNOS activity in both peripheral
and central compartments. In the periphery, the NO production decrease may reflect an arginase-mediated synthesis of
polyamines necessary to trypanosome growth. In the brain, the increased NO concentration may result from an enhanced
activity of iNOS present in neurons and glial cells. It may be regarded as a marker of deleterious inflammatory reactions.
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Introduction
Human African trypanosomiasis (HAT), or sleeping sickness, is
a reemerging parasitic disease caused by protozoan parasites
belonging to the genus Trypanosoma. The disease, always fatal if
untreated, is transmitted by the bite of an infected insect vector,
the tsetse fly. Two sub-species of Trypanosoma infective to humans
are present in 36 Sub-Saharan African countries. Two clinical
entities exist due to the geographic distribution of Trypanosoma sub-
species. Trypanosoma brucei (T. b.) gambiense, found in West and
Central Africa, causes a chronic infection with slowly evolving
symptoms (months to years) whereas T. b. rhodesiense, found in East
Africa, is responsible for an acute sickness (weeks to months). In
both clinical entities, two distinct stages occur successively during
the course of the disease. The early stage, or hemolymphatic stage
1, corresponds to parasite proliferation in blood and lymphatic
systems, the parasites invading progressively peripheral vital
organs. The late or meningoencephalitic stage 2 is characterized
by the crossing of the blood-brain barrier (BBB) with the invasion
of the central nervous system (CNS) by the parasites [1]. Although
they may be observed throughout the course of the disease,
neurological signs are most often described during stage 2, with a
wide panel of sensory, motor and psychiatric disturbances, and the
development of disruptions of the sleep-wake cycle, a most
characteristic sign that gave its name to the illness [2]. A similar
time course with two successive clinical stages together with sleep-
wake cycle disturbances has been described in animal models
infected by T. b. brucei [3].
In recent years, immune and neurological reactions to
trypanosomal infection have been related to a gaseous signaling
molecule, nitric oxide (NO) that represents an essential messenger
between trypanosomes and the immune and nervous systems [4].
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enzymatic family of NO synthases (NOS) that consist of three
major isoforms: neuronal NOS (nNOS, type 1), inducible/or
macrophagic NOS (iNOS, type 2) and endothelial NOS (eNOS,
type 3) [5]. The NO generated by iNOS is a key cytotoxic weapon
used by the innate response for the destruction of trypanosomes
[6] through the combination of NO and oxygen reactive species.
However, proliferation of trypanosomes in the vicinity of
peripheral macrophages in infected mice suggested the existence
of a reduced efficiency of NO-dependent cytotoxicity. The
competition between arginase and iNOS for their common
substrate, L-arginine, reduces NO production and favors poly-
amine synthesis, required for trypanosome development [7]. Using
specific voltammetric sensors [8] in vivo, our team has previously
reported that NO is decreased in the blood of rats [9] and mice
infected by T. b. brucei [10] and in humans infected with T. b.
gambiense [10].
In the CNS, studies using a combination of polysomnographic
recordings and micropharmacological treatments employing NO
synthesis inhibitors or NO donors, have shown that NO is clearly
involved in the modulation of the sleep-wake states [11]. In the
experimental rat model of HAT, the hypothalamus, possessing a
neuronal network involved in the regulation of the sleep-wake
states [12], seems to be particularly vulnerable. Pro-inflammatory
cytokines (IL-1, TNF-a) and activation of microglia were detected
in periventricular cavities and most importantly in the hypotha-
lamic area [1]. Such a pathological evolution might be at the
origin of circadian rhythm and neurological disturbances. In
our previous voltammetric studies, we demonstrated that NO
concentration is increased in the brain cortex of rats and mice
[9,10]. This up-regulation of the NO pathways remains, however,
to be further investigated, notably in the hypothalamus since the
respective role played by the different NOS isoforms in the NO
enhancement remains to be defined more precisely.
The present study, using an experimental rat model of human
sleeping sickness (HAT), was designed to evaluate the changes
occurring in NO production throughout the time-course of T. b.
brucei infection. We chose to compare brain tissue and blood
because these compartments are also those currently investigated
in HAT: cerebrospinal fluid (CSF) for the brain tissue and blood
for periphery. We emphasized the fact that the impairments taking
place in these compartments reflect the two stages of the disease.
To achieve this objective, the first step was to confirm that the
experimental disease evolved in two successive stages by measuring
body weight and the parasitic charge in the peripheral (blood) and
cerebral (CSF) compartments. Afterwards, we focused on the
original part of our approach, i.e., the changes occurring in NO
concentration in the two compartments, together with an
evaluation of enzymatic activity (nNOS and iNOS) and the
identification of the cell types in which the NO-pathways are
particularly active during the course of the infection.
Materials and Methods
Animals
Male rats (Wistar strain, 200–220 g, Janvier breeding, Le
Genest Saint Isle, France), housed in individual cages, were kept
under standard laboratory conditions (12/12h light/dark cycle,
light-on at 5.00 a.m.; 2261uC; water and food ad libitum). After 8
days of adaptation to the experimental conditions, the animals
were randomly divided in two groups, a control (24 animals) and
an infected group (24 animals). All experiments were performed
according to the guidelines of the French Agriculture Ministry
(Nu: 03-505).
Infection, Body Weight Follow-Up, Parasitemia and
Cerebrospinal Fluid (CSF) Trypanosome Count
Rats were infected by intraperitoneal (i.p.) injection of 3600
parasites (T. b. brucei AnTat 1.1E clone, provided by Institute of
Tropical Medicine, Antwerp, Belgium) per animal. Prior to the
injection, mobility of trypanosomes was observed under micro-
scope. In parallel, control animals received an i.p. injection of the
same volume of saline solution. Body weight and blood parasite
counts were monitored every two days, while CSF parasite counts
were performed every four to five days. CSF samples were
obtained by cisterna magna puncture from anesthetized (chloral
hydrate, 400 mg/kg) rats kept in a stereotaxic frame with body
temperature maintained at 37uC by a homoeothermic blanket
(Harvard apparatus, Les Ulis, France). After reclining the neck
muscles from the midline, CSF was collected with a syringe guided
in the cisterna magna by way of a stereotaxic holder. Before reaching
the cisterna magna, the needle was inserted gently through the
meninges.
Dissection and Tissue Preparation
The rats were sacrificed by decapitation at days 5, 10, 16 or 22
post-infection (D5, D10, D16 and D22). This timing was chosen
from previously published data [3] as representing the middle of
the first hemolymphatic stage (D5), the limit between stages 1 and
2 (D10), the well-established neurological stage 2 (D16) and the pre-
mortem condition (D22). Blood was sampled by direct heart
puncture. Macrophages were collected by washing the peritoneal
cavity with a saline solution (NaCl 0.9%) containing heparin
(0.4%) and polymyxine B (1 mg6L
21). Brains were quickly
removed, briefly rinsed in ice-cold Tris-EDTA buffer (50 mM,
pH 7.4) and dissected to collect hypothalamic and thalamic
structures.
Protein extracts from brain tissue. After dissection,
hypothalamic and thalamic samples were homogenized by
sonication in 1 mL of ice-cold Tris-EDTA buffer (50 mM,
pH 7.4) containing EDTA (1 mM), dithiothreitol (1 mM) and
protease inhibitor cocktail (Sigma-Aldrich, St Quentin-Fallavier,
France,). Homogenates were centrifuged at 15,000 g for 45 min at
4uC and aliquots of the supernatants were collected and stored
at 280uC until biochemical assay. Protein concentration in
supernatant fractions was determined using Bradford’s method
[13].
Protein extracts from peritoneal macrophages. The
collected peritoneal cells (in suspensions) were centrifuged at
1,000 g (22uC, 5 min), and placed in MEM containing 2% fetal
calf serum and 1% penicillin-streptomycin. Afterwards, cells
(1610
6/2mL/well) were layered on 6-well plates and maintained
at 37uC under 5% CO2 atmosphere during 2 hours. Non-
adherent cells were removed by three successive washings with
phosphate buffer saline (PBS, pH 7.4) and adherent cells
(macrophages) were used for protein extraction as described
above for brain extracts. Protein concentration in supernatant
fractions was determined using Bradford’s method [13].
NO Measurements
In vivo NO measurements in the brain. Detection of NO
was achieved using a NO sensor in combination with differential
normal pulse voltammetry (DNPV) as previously described [8]. NO
measurements were performed under chloral hydrate anesthesia
(400 mg/kgi.p. injection). Animalswere kept ona stereotaxicframe
with body temperature maintained at 37uC by a homoeothermic
blanket (Harvard apparatus, Les Ulis, France). The superficial
cutaneous and muscular layers were resected and bone trepanation
NO in Sleeping Sickness
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mater (external meninge), the NO sensor was stereotaxically
introduced into the internal medullar lamina of the thalamus
(H=+5.5 mm; P=23.14 mm/Bregma; L=+1.4mm), and then
into the perifornical nucleus of the hypothalamus (H=+8.5mm;
P=23.14mm/Bregma; L=+1.4mm) according to Paxinos and
Watson’s atlas(4
thedition 1998) [14].Reference(Ag/AgCl,250 mm
in diameter) and auxiliary (tungsten wire, 250 mm in diameter)
electrodes were implanted in contact with external meninge. The
differential NO oxidation current (650 mV vs Ag/AgCl) was
measured with the instrumental set-up as already detailed [15]. The
output signal intensity was recorded and quantified using a specially
designed software (Saphir, Chapareillan, France). Measurements of
stabilized signals were taken every 2 min. The experiments were
performed in control and infected rats at D5, D10, D16, and D22
days post-infection (6 animals per experimental day of each group).
For each infected animal, data were expressed as percentages of
healthy controls. At the end of each experimental session, the
position of the NO sensor was verified (current of 1 mA through the
NO sensor). Brain was removed, frozen and sliced (coronal sections
20 mm thick) using a cryostat (Microcom France, Francheville,
France). Brain sections were stained with cresol purple to confirm
the correct position of the NO sensor.
NO measurements in blood. Immediately after sampling
by direct puncture of the heart with a heparinized syringe, blood
was introduced into an airtight gas chamber (0.4 mL) containing
the NO sensor, reference and auxiliary electrodes as previously
described [16]. Measurements were performed with the same
instrumental set-up described previously [15].
NOS Activity
NOS activity was measured by the conversion of [
3H]L-arginine
to [
3H]L-citrulline according to the procedure described by
Cle ´ment et al. [17]. For total NOS activity, 20 mL (about 100 mgo f
protein) of protein extracts from the cytosolic fraction (containing
predominantly nNOS/iNOS) were incubated at 37uC for 20 min
in buffer A with a final volume of 100 mL (HEPES 50 mM,
pH 7.2 containing valine 50 mM, CaCl2 1.25 mM, L-citrulline
1 mM, L-arginine 40 mM, L-ornithine 1 mM, NADPH 1 mM,
EDTA 125 mM, (6R)-tetrahydrobiopterin 100 mM, FAD 5 mM,
FMN 5 mM, calmodulin 1 mg, dithiothreitol 1 mM, and [
3H]-L-
arginine 87 nCi (41 Ci6mmol
21, Perkin Elmer Life Sciences,
Courtaboeuf, France). Measurements of iNOS activity were
performed in a buffer containing 5 mM EGTA as a calcium
chelator. Blank values were obtained using buffer A plus NOS
inhibitors, N
v-monomethyl-L-arginine (1 mM), N
v-nitro-L-argi-
nine (10 mM), N
vnitro-L-arginine-methyl ester (10 mM) from
Sigma-Aldrich and EGTA (5mM). The reaction was stopped by
adding 2 mL of ice-cold buffer B (HEPES 20mM, EDTA 2mM,
pH 5.5). Then, 1 mL of aqueous suspension of Dowex 50WX-8
resin (1/1 w/v), equilibrated with buffer B, was added. After
agitation during 15 min, each tube was centrifuged for 3 min at
500 g and the supernatant was recovered. The resin was rinsed
with 2 mL of distilled water. [
3H]L-citrulline was quantified using
a liquid scintillation analyzer (1900 TR, Packard Instrument,
Rungis, France). Total NOS activity was calculated by subtracting
blank values from the NOS assay. Activity of nNOS was estimated
by subtracting iNOS activity value from total NOS activity value.
All assays were made in duplicate and specific activity of NOS
corresponding to picomoles of citrulline formed per min and per
mg of protein (pmol/min/mg protein) was expressed as percentage
of the values obtained in the non-infected condition. Peritoneal
macrophages, collected from healthy rats treated or not by
lipopolysaccharides (LPS), together with commercially available
iNOS from mouse macrophages (50 U, CALBIOCHEM, France
Biochem, Meudon, France), were used as iNOS activity control.
Immunohistochemistry and Immunofluorescence
After anesthesia with chloral hydrate (400 mg/kg, i.p. injection),
animals were perfused with Ringer lactate/heparin (0.05%)
solution, followed by a cold mixture (PBS pH 7.4 containing
paraformaldehyde at 4% and glutaraldehyde at 0.1%). Afterwards,
brains were removed and immersed overnight at +4uC in a fixative
mixture of PBS pH 7.4 containing 4% paraformaldehyde and
then immersed for 3 days at +4uC in a sucrose solution at 30%.
After being frozen in 2-methylbutane (Sigma-Aldrich) at 240 to
260uC, brain cryosections (25 mm thick) were obtained and
collected in PBS containing 0.3% Triton X-100 (PBS-T) with 2%
hydrogen peroxide then in PBS-T containing 0.01% sodium azide
until use.
Immunostaining of iNOS and nNOS. As previously
described [17], mouse anti-iNOS monoclonal antibody (1/
10000, Sigma-Aldrich) or rabbit anti-nNOS polyclonal antibody
(1/200, Santa Cruz Biotechnology, Santa Cruz, California, USA)
were used as primary antibodies. Biotinylated horse anti-mouse
(1/2000, Vector Labs, ABCYS, Paris, France) or biotinylated goat
anti-rabbit (1/200, Vector Labs) were used as secondary
antibodies. Peritoneal macrophages activated with LPS (0127-B8
and 0111-B4, 5mg/mL, Sigma-Aldrich) were used as positive
iNOS controls 8 and 24 h after exposure to LPS.
Double labeling of iNOS with brain cell types: iNOS and
neurons (iNOS/NeuN), iNOS and astrocytes (iNOS/GFAP),
iNOS and microglia (iNOS/Integrin aM). We used mouse
anti-iNOS monoclonal antibody (1/10000, Sigma-Aldrich), mouse
anti-NeuN antibody conjugated with Alexa Fluor 488 (anti-
NEUronal Nuclei, Alexa Fluor 488 conjugated, 1/500, Millipore,
Molsheim, France), rabbit anti-GFAP polyclonal antibody (anti-
Glial Fibrillary Acidic Protein, 1/500, Dako laboratories,
Carpentaria, California, USA) and mouse anti-Integrin aM
(OX42) FITC conjugated antibody (1/500, Santa Cruz
Biotechnology). As secondary antibodies, we used a goat anti-
mouse antibody conjugated with Alexa Fluor 488 or 568 (1/500,
Invitrogen- Life Technologies, Cergy-Pontoise , France) and a
goat anti-rabbit antibody conjugated with Alexa Fluor 568 (1/500,
Invitrogen). Visualization was achieved using a Vectashield
mounting medium with DAPI (nuclear stain, Vector Labs) under
a fluorescence microscope. Peritoneal macrophages activated with
LPS (0127-B8 and 0111-B4, 5mg/mL, Sigma-Aldrich) during 24 h
were used as positive iNOS controls.
Trypanosome labeling. Anti-T. b. brucei AnTat 1.1E from
immunized mouse (1/400) and goat anti-mouse secondary
antibody conjugated with Alexa Fluor 568 (1/500, Invitrogen)
were used. Sera from non-infected mice were used as controls.
Statistical Analysis
Results are expressed as mean 6 SEM (n=6 if not otherwise
specified) of the different variables analyzed. Statistical analysis of
differences between rat groups was performed using ANOVA.
When ANOVA was significant at p,0.05, a post hoc Fisher’s least
significant differences test was applied.
Results
The Two-Stage Disease Course in T. b. brucei-Infected
Rats
Stage determination was evaluated by measuring body weight
gain, trypanosome counts in the blood and CSF, and trypanosome
immunostaining in the brain (from D0 to D22 post-infection).
NO in Sleeping Sickness
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gain was observed between control and infected rats. Control rats
maintained a steady weight gain and a good health status (Fig. 1A).
Infected animals experienced a significant body weight gain
decrease from D10 (77.6763.18 g vs 94.5062.86 g in control rats)
to D22 (126.83615.63 g vs 195.2067.32 g). Moreover, trypano-
somes appeared in the blood five days after the intraperitoneal
inoculation. As shown in Fig. 1B, parasitemia evolved in four
successive waves occurring at intervals of 4–5 days with peak
values at D7, D12, D16 and D22 post infection. The presence of
trypanosomes in the CSF was detected at D10 post infection in
66% of the infected animals. At this time, parasites were not
observed in the brain parenchyma. At D16 and D22 post
infection, trypanosomes were found in the CSF and brain tissues
(Fig. 1C) of all the animals (Table 1, n=3 per day). The
trypanosomes were observed mainly around the ventricular
cavities (circum-ventricular organs).
Opposite Changes Occurring in NO Synthesis between
Brain and Blood
In the brain, NO was measured successively in two different
structures (hypothalamus and thalamus) in the course of the
disease (from D5 to D22). As compared to control rats, infected
animals exhibited a progressive increase in the extracellular
concentration of NO. In the hypothalamus, the increase reached
statistical significance at D16 (+71%, Fig. 2A). Afterwards, NO
levels returned towards control values at D22. In the thalamic
area, the changes were similar to those observed in the
hypothalamus. After infection, the magnitude of NO concentra-
tion was maximal at D16 (+55% increase, Fig. 2A) compared to
the value measured in non-infected control rats.
In the blood, a significant and progressive decrease in NO
concentration was observed in infected rats (60% decrease
between D5 and D22; Fig. 2A) as compared to the concentrations
obtained in control animals.
Cerebral and Peripheral Variations Occurring in NOS
Activity
The NO production in the brain, may result from the activity of
either nNOS or iNOS, while peripheral NO depends mainly on
iNOS activity. In the hypothalamic and thalamic areas, no
significant changes between control and infected animals were
observed for nNOS activity in any examined slice between D5 and
D22 post infection (Fig. 2B). On the contrary, infected animals
experienced an important rise in iNOS activity from D10 to D16,
the greatest elevation in enzyme activity occurring on D16 (up to
+700% compared to controls). Afterwards, iNOS activity returned
to control values on D22 (Fig. 2C).
In peritoneal macrophages, iNOS activity measures revealed
opposite changes in comparison to brain data. An increase in the
activity of the enzyme was observed in infected rats on D5 (+150%
compared to non-infected controls). This variation was then
followed by a drastic drop in the enzyme activity at D10 (285%
decrease compared with non-infected controls). Then, iNOS
activity reached a plateau until D22 (275% decrease) (Fig. 2D).
Immunohistochemistry of iNOS and nNOS
In order to identify the cell types specifically involved in NO
synthesis catalyzed by iNOS activity, an immunohistochemical
study was performed in the sampled brain areas. With regard to
iNOS, a cytosolic immunoreactivity was clearly evident at D16 in
infected rats in several brain areas (pontine structures, cortical
areas, amygdala, hippocampus, suprachiasmatic nuclei, Fig. 3A).
Figure 1. Biological diagnostic of experimental African try-
panosomiasis in Wistar rats infected with T. b. brucei. (A) Body
weight gain in healthy and infected rats calculated from weight values
at D0 before infection: mean value6SEM (*p ,0.05 compared to
healthy rats, n=6 per day and per group). (B) Time course of
parasitaemia, n=6 per day). (C) Immunofluorescent staining of T. b.
brucei (red) in the brain parenchyma at D16 post infection (n=3). Nuclei
were stained with DAPI (blue). (Microscope Olympus BX51equipped
with Olympus DP50 camera). Statistics analysis, ANOVA followed by
post hoc Fisher’s test. Abbreviations: T. b. brucei, Trypanosoma brucei
brucei; DAPI, 49,6 9 Di Amidino-2-Phenylindole.
doi:10.1371/journal.pone.0009211.g001
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immunoreactivity was located in neurons within the perifornical
nucleus (PeF), supraoptic nucleus, retrochiasmatic (SOR), magno-
cellular nucleus of the lateral hypothalamus (MCLH), and lateral
hypothalamic area (LH) structures [15], as well as in microglial
cells within the periventricular hypothalamic nucleus (Pe). The
iNOS labeling involved both cell types in the ventromedial
hypothalamic nucleus (VMH). In the thalamus, the iNOS staining
was particularly obvious around the dorsal part of the third
ventricle (D3V) particularly in the paraventricular thalamic
nucleus, posterior (PVP), and habenular nucleus (Hb) (Fig. 3A).
The specificity of the anti-iNOS antibody employed was verified
by an immunocytochemical investigation using LPS-treated or
non-treated peritoneal macrophages. A loss of staining was
observed when the anti-iNOS antibody was omitted in the
immunocytochemical procedure (Fig. 3B a). However, most cells
became strongly positive after LPS treatment (Fig. 3B c and e) as
compared to untreated cells (Fig. 3B b and d). Concerning nNOS,
although the immunostaining was clearly expressed in the brain,
no significant differences were detected between non-infected
controls and infected rats (data not shown).
Immunofluorescence Identification of iNOS Expressing
Cells
Double iNOS/NeuN labeling (NeuN for neuronal cell bodies)
and iNOS/DAPI labeling (DAPI for nuclei) revealed a clear
cytosolic iNOS activity in neurons in infected rats. The iNOS
activity was also present in astrocytes as shown by iNOS/GFAP (a
specific marker for astrocytes) double labelling. When performing
iNOS and Integrin aM double labelling (a specific marker for
microglial cells), iNOS was alsodetected in microglial cells (Fig. 4A).
The specificity of the immunofluorescence yielded by the iNOS was
verified using peritoneal macrophages treated or not-treated with
LPS during 24 h. A lack of immunofluorescence occurred in the
macrophages that were not treated with LPS (Fig 4B).
Discussion
In the present investigation, rats infected with T. b. brucei AnTat
1.1E were used as an experimental model for HAT. Our attention
was especially focused on NO due to its trypanocidal properties
[6]. Data reported here addressed: (i) the parameters necessary for
a routine assessment of the two successive stages of the disease
(body weight gain, parasitemia time course, CSF parasite counts),
(ii) the changes in NO concentration occurring in the course of the
neurological disease and the related NOS activity, as well as the
identification of the cell types in which the cerebral NO-pathway
changes take place.
Table 1. Presence of trypanosomes in the CSF of
T. b. brucei-infected Wistar rats.
Days post-infection D5 D10 D16 D22
004 1 1
Parasites
number per
mL*
02 2 2 3
042 6 7
*Three infected animals per day.
T. b. brucei=Trypanosoma brucei brucei.
CSF=Cerebrospinal fluid.
doi:10.1371/journal.pone.0009211.t001
Figure 2. Changes occurring in NO synthesis in the brain and
peripheral compartments of experimental African trypanosomi-
asis in Wistar rats infected with T. b. brucei. Variations in NO
concentration or NOS activity (mean value 6 SEM, n=6 per day) were
normalized with corresponding values measured in control rats (100%).
(A) Relative concentration of NO analyzed in the blood, and in thalamic
and hypothalamic areas. (B) Relative nNOS activity in thalamic and
hypothalamic extracts. The 100% control value, delineated by the dotted
line, corresponds to 337.8634.5 pmol/min/mg. (C) Relative iNOS activity
in thalamic and hypothalamic extracts. 100% correspond to
2.661.6 pmol/min/mg. (D) Relative iNOS activity in peritoneal macro-
phages. 100% correspond to 495.76165.5 pmol/min/mg. Statistics
analysis, ANOVA followed by post hoc Fisher’s test. (*p,0.05,
**p,0.001, ***p,0.0001 compared to healthy rats) Abbreviations: NO,
nitricoxide;NOS,NO-synthase;iNOS, inducibleNOS; nNOS,neuronalNOS.
doi:10.1371/journal.pone.0009211.g002
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observed in different regions of the hypothalamus and thalamus. Perifornical nucleus (PeF); supraoptic nucleus; retrochiasmatic (SOR); magnocellular
nucleus of the lateral hypothalamus (MCLH); lateral hypothalamic area (LH); periventricular hypothalamic nucleus (Pe); ventromedial hypothalamic
nucleus (VMH); paraventricular thalamic nucleus, posterior (PVP); habenular nucleus (Hb). (B) Controls of iNOS labelling: peritoneal macrophages were
incubated with (B-c, e) or without (B-b, d) LPS during 8 h (B-b, c) or 24 h (B-d, e). Specificity of secondary antibody was verified in incubating
peritoneal macrophages without anti-iNOS antibody (B-a). Number of animals, n=4 per group. The microscope used was an Olympus BX51 equipped
with Olympus DP50 camera (objective640). Abbreviations: iNOS, inducible NO-synthase; LPS, lipopolysaccharide.
doi:10.1371/journal.pone.0009211.g003
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PLoS ONE | www.plosone.org 6 February 2010 | Volume 5 | Issue 2 | e9211Figure 4. Localization of iNOS in neurons, astrocytes and microglia in T. b. brucei-infected rats. (A) The immunofluorescent staining of
iNOS (red and green) was performed in the hypothalamic area. The different cell types in which iNOS was expressed were stained (double labelling)
using NeuN (green) for neurons, GFAP (red) for astrocytes, and integrin aM (red) for microglia. (B) Controls of iNOS labelling: peritoneal macrophages
were incubated with (B-f, g, h) or without (B-b, c, d) LPS during 24h. Specificity of secondary antibody was verified in incubating peritoneal
macrophages without anti-iNOS antibody (B-a, e). Nuclei were stained with DAPI (B-c, g, blue). Number of animals, n=4 per group. The microscope
employed was an Olympus BX51 equipped with Olympus DP50 camera (objective640). Abbreviations: iNOS, inducible NO-synthase; DAPI, 49,6 9 Di
Amidino-2-Phenylindole; NeuN, Neuron Nuclear; GFAP, Glial Fibrillary Acidic Protein; LPS, lipopolysaccharide.
doi:10.1371/journal.pone.0009211.g004
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Stages of the Disease
At D5 post-infection, the clinical signs characterizing the later
meningoencephalitic phase were still absent. Weight gain did not
differ between infected and control animals. Parasites appeared in
blood but not in CSF samples. Considering the comparison with
HAT, the infected animals were most certainly still in the
hemolymphatic phase at D5 post-infection. At D10 and D16,
the existence of a significant slowing in the rate of growth together
with the presence of trypanosomes in the CSF indicated that the
infected animals had entered the second or neurological stage of
the disease. Furthermore, since body weight control resides at least
partly in the hypothalamus, the decrease in growth progression
observed might be considered as an early peripheral sign of
neurological disturbances. In previous reports from our team
[3,18], the slowing in the rate of growth was considered to be
characteristic of the second phase. It occurred a few days after the
decrease in food intake and was associated with anemia and the
infiltration of mononuclear inflammatory cells in the brain [3,18].
We also demonstrated that trypanosomes can be present in the
CSF in the absence of clinical symptoms [19]. We found that
staining of trypanosomes in the brain was evidenced at D16,
confirming previous observations done in the Sprague Dawley rat
model [20]. Trypanosomes were observed around the ventricular
cavities in areas where the BBB is most permeable, i.e., at the level
of circumventricular organs, median eminence and subfornical
organ of the hypothalamus [21]. Such localizations may contribute
to disturbances observed in HAT (weight gain reduction [18],
sleep and wake disturbances [2], endocrine modifications [2] and
temperature deregulation [18]).
(ii) Changes in the NO Production and Related Regulatory
Processes
In the blood, the decrease in the NO fraction was evident
mainly during the later stage of the disease, in agreement with
previous observations from our team (mouse, rat, and human
[9,10]). These changes are likely to result from an impaired iNOS
activity, which was found to occur in peritoneal macrophages
collected from the same animals. Such a decrease in NO
concentration has also been reported in mononuclear cells
collected from the blood of T. congolense-infected cattle [22].
Moreover, a contribution of eNOS cannot be excluded, since an
increase in eNOS activity has been reported in mice infected with
T. b. brucei [23]. Even though such an effect exists, its magnitude
would not be capable of counteracting the highly significant
decrease observed in blood NO concentration.
The impaired blood NO production may result from an
imbalance in the stimulatory/inhibitory elements of the immune
system. The iNOS activity is up-regulated mainly by the pro-
inflammatory cytokines IFN-c, TNF-a and IL-2, and down-
regulated by the immunosuppressive cytokines IL-10, IL-4 and
TGF-b [24]. The latter three cytokines are recognized as very
potent inhibitors of IFN-c-stimulated monocyte-macrophage
effectors function, including NO synthesis and microbicidal
activity. During the early stage of the infection, secretion of pro-
inflammatory cytokines (IFN-c, TNF-a) and NO by macrophages
provides the host protection by inhibiting parasitic development
and helping the host to prolong specific immune defenses [25].
However, immunosuppressive cytokines such as IL-10, IL-4 and
IL-13 (anti-inflammatory effect) are significantly elevated in the
later stage of the infection [25,26]. IL-10 inhibits specifically TNF-
a, and its excessive production may contribute to trypanotolerance
and immunosuppression [27]. However, the down-regulation
exerted on the iNOS by IL-10 and other anti-inflammatory
cytokines is not sufficient to explain the decreased NO production
observed in the blood at the neurological stage of the infection.
Anti-inflammatory interleukins such as IL-4 and IL-10 are
inducers of arginase isoforms, although these cytokines are known
to act on the expression of arginase I, but not that of arginase II
[28]. Arginase activation may also result from a direct interaction
of trypanosome products on cells of the immune system causing
the production of polyamines, which are essential for trypanothion
synthesis, and therefore for the growth and survival of trypano-
somes [25]. NO production may therefore be reduced in
macrophages through the competition of arginase with iNOS as
both enzymes use the same substrate, L-arginine. This aminoacid
is indeed decreased in the plasma of infected mice [29].
Furthermore, the circulatory decrease in NO might also be due
to the competition between L-arginine and ADMA (asymmetric
dimethylarginine), a potent endogenous inhibitor of NO synthesis
[30].
In the brain, NO production increased and the higher values
were observed at D16 after infection. Excessive NO production
can lead to alterations of neuronal signaling and to cell damage
through the cytotoxicity of NO oxidation derivatives. When NO is
released in large quantities, it may combine with the superoxide
anion (O
.2
2) to form peroxynitrite (ONOO
2), a free radical brain
tissue scavenger. Such an increase in NO production has been
observed in the cortex of mice infected by T. b. brucei at D15 and
D28 after infection [10]. In the present investigation, iNOS
activity varied similarly and exhibited a marked increase at D16
after infection. This aspect is also confirmed by immunohisto-
chemical data demonstrating iNOS immunoreactivity at NO
measurement sites, noticeably in the thalamus and hypothalamus.
These findings corroborate those obtained with NO voltammetric
measurements and suggest that iNOS is involved in the
overproduction of NO during the second stage of the infection.
This view is further reinforced by the facts that in our experiments:
(i) no significant variation was noticed in nNOS activity/protein
and mRNA expression (data not shown); (ii) a specific iNOS
inhibitor was capable of reducing the increase in NO production
measured in the cortex of mice infected with T. b. brucei (data
previously reported from our team [31]).
Moreover, in the posterior hypothalamus, iNOS immunoreac-
tivity was found to be located in neurons particularly in the
perifornical area as well as in the lateral part of the hypothalamus,
where the hypocretin neurons implicated in sleep/wake regulation
are located. These neurons play a crucial role in the maintenance
of a consolidated period of wakefulness [32]. Their loss or a
mutation of the gene encoding for hypocretin receptors are
accompanied by narcoleptic attacks with SOREMPs (sleep-onset
REM periods), in humans and animals [32]. Although SOREMPs
are also observed in HAT, our group has demonstrated that they
do not depend on a lack of hypocretin availability since the
concentration of CSF hypocretin was found to be near normal
control values in HAT patients [33]. The above aspects remain,
nevertheless, to be further investigated.
Besides the neuronal expression, iNOS immunoreactivity was
also observed in glial cells (astrocytes and microglia) at the second
stage of the disease (part of the involved cellular elements also
comes from infiltrating macrophages [34]). Astrocytes and
microglia may also display such macrophage-related functions in
relation with an iNOS-related production of NO. Other
investigations reveal also that, in vitro and in presence of T. b.
brucei, IFN-c (produced in the brain by infiltrated CD8+ T cells
[34]) stimulates the production of NO in astrocytes and microglia
through the activation of iNOS at the transcriptional level [35].
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induced by parasite components and/or autoimmune reactions, as
molecular mimicries were found between neurological compo-
nents and trypanosomes [27]. This could explain that, after the
increase in cerebral NO observed at D16, NO production
decreased at D22 post-infection. Two reasons may lead to this
observation. It has been suggested that nitrate (an inert metabolite
of NO) concentration in the brain of mice infected by T. b. brucei
decreases in the late or final phase of CNS infection (pre-mortem
phase with more severe inflammation) [36]. Such a decrease might
reflect an extremely deleterious pre-mortem situation during which
anti-inflammatory processes seem to be protecting the brain from
severe inflammation such as observed in autoimmune encephalitis
[37]. Recent studies suggest that inhibition of the kynurenine
pathway in the late CNS stage of infection can reduce the severity
of host inflammation response [38]. It may also simply reflect a pre-
mortem general immunosuppressive syndrome [27].
Conclusion. Direct measurements of NO allowed an analysis
of the mechanisms regulating NO production throughout the
time-course of infection in a T. b. brucei-infected rat model of HAT.
In the periphery (macrophages and blood), NO production
decreased. This aspect is triggered by a complex cascade of
events involving cytokines and most likely the arginase pathway. It
allows the reduction of the trypanocidal pressure exerted by NO
towards trypanosomes, thus constituting a potential target for the
development of a new adapted pharmacotherapy. Conversely, the
NO production increased in the brain. Such a deleterious rise in
NO resulted essentially from the enhanced iNOS activity in
neurons, astrocytes and microglial cells. It might serve as a marker
of the deleterious inflammatory situation of the brain.
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